Evidence mapPaperPMID 41603034Full record

ReviewHypertension (Dallas, Tex. : 1979)2026

Hypertension in Patients With End-Stage Kidney Disease Requiring Dialysis: Bridging the Divide Between Evidence and Practice.

Laura Mayeda, Nisha Bansal

Abstract readReview
In one paragraph

Review in Hypertension (Dallas, Tex. : 1979), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Laura MayedaDivision of Nephrology, University of Washington, Seattle.ORCID 0000-0002-9255-5673
Nisha BansalDivision of Nephrology, University of Washington, Seattle.ORCID 0000-0002-9583-8628

Funding

Home Blood Pressure in Hemodialysis (HOME-BP)R01DK123104 · UNIVERSITY OF WASHINGTON · 2025 to 2025
$628k
Mentored research in the intersection of kidney and cardiovascular diseaseK26DK138333 · UNIVERSITY OF WASHINGTON · 2025 to 2025
$110k
NIDDK NIH HHS K26 DK138333NIDDK NIH HHS R01 DK123104
6 · The paper itself

Abstract

Hypertension is a highly prevalent and modifiable risk factor, affecting >80% of patients undergoing dialysis. Its pathophysiology is complex and differs from that of the general population, driven by factors such as volume overload, arterial stiffness, overactivation of the sympathetic and renin-angiotensin-aldosterone systems, and endothelial dysfunction. Achieving optimal blood pressure and volume control is central to dialysis care, with significant implications for cardiovascular outcomes and patient quality of life. Despite its importance, evidence guiding hypertension management in this population remains limited. Furthermore, reliable, objective methods to assess extracellular volume are lacking. This review examines current approaches to the assessment and management of hypertension in maintenance hemodialysis, summarizing existing evidence, clinical guidelines, and ongoing challenges in blood pressure and volume control.

Indexed as

HypertensionKidney Failure, ChronicRenal DialysisAntihypertensive AgentsBlood PressureHumansPractice Guidelines as TopicRenin-Angiotensin SystemRisk FactorsAntihypertensive Agentsblood pressuredialysishypertensionkidneyrenal insufficiencyrenin-angiotensin system

Identifiers

PMID41603034
PMCPMC12854527

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.